<h1>Company posts strong interim results as diabetes drug commercialization accelerates, one-time deferred income release boosts profit</h1> The company reported strong interim results driven by accelerated commercialization of its core diabetes drug after terminating an exclusive promotion agreement with a former promotion partner, which triggered a one-time release of deferred income of RMB1,243.5 million and produced a pre-tax profit of RMB1,183.9 million for the period. Net sales rose 112% year-on-year with improved gross margin (54.2%) and cash of RMB1,022.8 million. Reimbursement listing expansion and an in-house sales force boosted prescriptions. Ongoing real-world studies and regulatory filing in Hong Kong underpin pipeline progress, while forward-looking statements note risks and uncertainty that may affect future results.